Omikron: Biontech and Pfizer produce customized vaccine

The Mainz-based pharmaceutical company Biontech and its US partner Pfizer have started production of a corona vaccine adapted to the Omikron variant for later commercial use. This was announced by Biontech boss Ugur Sahin on Tuesday at a health conference of the US bank JP Morgan. A clinical study on the vaccine will begin at the end of January.

“We assume that we will be ready to deliver to the market by March, if the regulatory approvals are in place.” The European Medicines Agency (EMA) has not yet stated whether it considers a vaccine adapted to Omikron with a different composition than the vaccine currently used to be necessary.

For the year 2022, Biontech and Pfizer expect a production capacity of up to four billion vaccine doses worldwide. “We expect that there will also be strong demand for our vaccine in 2022,” said Sahin in his online presence.

Pfizer boss Albert Bourla had also made a similar announcement earlier:

Leave a Reply